Richard E. Buller, an insider at Celcuity Inc (CELC), recently acquired 11,160 shares of the biotechnology company at a price of $14.83 per share, amounting to a total investment of $166,000 on November 19, 2025. Following this transaction, Buller now holds a total of 11,160 shares.
Celcuity operates as a cellular analysis company focused on developing therapies for advanced breast and prostate cancers. Its lead candidate, gedatolisib, targets specific cancer pathways and is currently undergoing a Phase III clinical trial (VIKTORIA-1) that evaluates its effectiveness in combination with other treatments for hormone receptor-positive, HER2-negative breast cancer.
With a market capitalization of $4.4 billion and a trailing twelve-month EPS of -3.45, Celcuity is positioned in a competitive sector that demands continuous innovation. Investors may look to upcoming earnings reports, with estimates predicting an EPS of -1.11 for May 12, 2026, and -1.16 for August 12, 2026.
Insider buying often serves as a signal of confidence in a company's future. However, it is essential for investors to consider such transactions within a broader context, analyzing multiple insider activities and other financial indicators rather than relying on isolated events for decision-making.